STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows ...

Sutro Biopharma, Inc. (STRO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Sutro Biopharma Inc STRO shares are trading lower by 2.8% to $5.18 during Tuesday’s session after the company announced the pricing of an underwritten offering of 14,478,764 shares of its common ...